Oligonucleotide Synthesis Market

The global oligonucleotide synthesis market in terms of revenue was estimated to be worth $8.8 billion in 2024 and is poised to reach $19.7 billion by 2029, growing at a CAGR of 17.5% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The major factors driving the growth of this market are the growing use of synthesized oligonucleotides for therapeutic and diagnostic applications, ongoing developments in technologies such as next-generation sequencing (NGS) and CRISPR, increasing investments by governments and major players in life science research and synthetic biology, and a growing focus on precision/ personalized medicines.

Oligonucleotide Synthesis Market- Global Forecast to 2029

Attractive Opportunities in Oligonucleotide Synthesis Market

To know about the assumptions considered for the study, Request for Free Sample Report

Global Oligonucleotide Synthesis Market Dynamics

Driver: Increasing use of synthesized oligos in therapeutic and diagnostic applications

The potential of oligonucleotide-based drugs to treat a diverse range of neurological and rare diseases is a major factor driving the growth of this market. There has been a consistent growth in the number of regulatory approvals received for these drugs. Additionally, a strong clinical pipeline exists for these drugs. Furthermore, oligonucleotides are used for genetic testing, molecular diagnostics, microarrays, and gene therapy applications. Synthesized oligos are used for accurate and sensitive detection and quantification of nucleic acids. Modified DNA/RNA oligonucleotides, such as fluorescent probes, are used to identify specific genetic sequences, allowing the detection and diagnosis of genetic disorders and infections. These applications of oligonucleotides are significantly driving the demand for synthesized oligonucleotides as well as oligonucleotide-based drugs.

Restraint: Complexities associated with therapeutic oligonucleotides

Achieving specific control over the length of the oligonucleotide while minimizing impurities is one of the major challenges faced during oligonucleotide synthesis. Waste generated during the synthesis process is another major issue related to oligonucleotide synthesis. Large amounts of nucleotides that are not incorporated into the oligonucleotide sequences are discarded as waste harmful waste. These factors, cumulatively, are restraining the growth of the market to a certain extent.

Opportunity: Increasing R&D investments by key players in emerging economies

Emerging economies like China, India, Japan, Brazil, and Argentina offer substantial growth opportunities for the oligonucleotide synthesis market. This is mainly due to the increasing investments by various major companies in emerging economies of the Asia Pacific and Latin America regions. For instance, in 2023, Merck KGaA, a major biotechnology company from Germany, invested USD 76 million (EUR 70 million) to expand production capabilities for high-purity reagents and increase the annual output at its site in Nantong, China. Similarly, in the same year, Insud Pharma S.L.U, a company based in Spain, opened a Spinal Muscular Atrophy (SMA) oligonucleotide development and manufacturing unit in India. This unit will focus on the production of Nusinersen, an antisense oligo that is used in the treatment of Spinal Muscular Atrophy (SMA). These developments indicate growing opportunities for players operating the market.

Challenge: Delivery of oligonucleotide drugs to specific targets

Oligonucleotide-based drug delivery is a major problem that reduces the effectiveness of oligonucleotide therapeutics. The intravenous delivery method used for the delivery of ASO drugs is not efficient, and often, drugs do not reach the target tissue in adequate quantities. Furthermore, the negative charge of these molecules makes crossing the blood-brain barrier a challenge for the drugs. Researchers are developing positively charged cell-penetrating peptides that have the ability to attach to the ASO drug allowing better cell penetration and drug availability. Thus, novel developments in this regard are expected to reduce the effect of this challenge in the coming years.

Ecosystem analysis

The ecosystem of the oligonucleotide synthesis market comprises supply side as well as demand-side entities that significantly contribute towards market growth. The demand side entities for therapeutic application (oligonucleotide-based drugs) include Hospitals mainly, while as for the research and diagnostic applications, major end users are pharma & biotech companies and diagnostic labs.

The oligonucleotide-based drugs segment accounted for the largest share in 2023.

Based on product the oligonucleotide synthesis market is divided into oligonucleotide-based drugs, synthesized oligonucleotides, reagents & consumables, and equipment. In 2023, the oligonucleotide-based drugs segment held the largest share of the oligonucleotide synthesis market. The major factors driving the growth of this segment are the increasing number of regulatory approvals received for oligonucleotide-based drugs, specifically antisense oligonucleotides and small interference RNA for the treatment of various neurological and rare diseases, growing research on the development of oligonucleotide-based drugs against common indications such as cardiovascular diseases that affect a larger patient population. Growing awareness of alternative therapies and the potential of these drugs to treat diseases that were previously deemed untreatable are among other factors that propel the market of oligonucleotide-based drugs.

The therapeutic application segment dominated the oligonucleotide synthesis industry in 2023.

Based on application, the oligonucleotide synthesis market is segmented into therapeutic, research, and diagnostic applications. In 2023, the therapeutic application segment held the largest market share as well as registered the highest market growth in the global oligonucleotide synthesis market owing to the increasing approval for oligonucleotide-based drugs such as ASOs and siRNAs for the treatment of various neurological and rare diseases. The focus of the industry leaders to expand the use of oligo-based therapies to common diseases such as cardiovascular disease will further propel the market of oligo based therapeutic drugs. Also, factors such as the increasing need for drugs with high specificity and efficacy including oligo-based drugs along with a growing focus on personalized/ precision medicine support market growth.

North America was the largest regional market for oligonucleotide synthesis industry in 2023.

The global Oligonucleotide synthesis market is segmented into six major regions—North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. North America was the largest segment in 2023 in the oligonucleotide synthesis market, followed by Europe and the Asia Pacific. North America, comprising the US and Canada, is the largest regional segment in the oligonucleotide synthesis market. This regional segment is projected to grow at the highest CAGR in the forecast period. The increasing R&D investments in the field of life sciences and healthcare and the growing focus on developing personalized therapeutics for various diseases are major factors supporting the large share of this market. The presence of a large number of global players in this region such as Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Maravai Lifesciences Holdings, Inc. (US), Azenta, Inc. (US), Twist Bioscience Corporation (US) among others, is another key factor contributing to the large share of this market segment.

To know about the assumptions considered for the study, download the pdf brochure

Key players in the market include Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai Lifesciences Holdings, Inc. (US), Azenta, Inc. (US), Twist Bioscience Corporation (US) and Genscript Biotech Corporation (US). Prominent players in the oligonucleotide-based drugs (therapeutic applications) market are Biogen Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Astrazeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US) and Novartis AG (Switzerland).

Get online access to the report on the World's First Market Intelligence Cloud

• Easy to Download Historical Data & Forecast Numbers
• Company Analysis Dashboard for high growth potential opportunities
• Research Analyst Access for customization & queries
• Competitor Analysis with Interactive dashboard
• Latest News, Updates & Trend analysis

Request Sample

Click on image to enlarge

Scope of the Report

This report categorizes the oligonucleotide synthesis market into the following segments and subsegments

By Product

• Oligonucleotide-based Drugs
  • Antisense Oligonucleotide-based drug
  • siRNA oligonucleotide-based drug
  • Other oligonucleotide-based drug
• Synthesized Oligonucleotides

By Product

• Primers
• Probes
• DNA Oligos
• RNA Oligos
• Other Synthesized Oligos

By Type

• Customized Oligos
• Predesigned Oligos
• Reagents & Consumables
• Equipment  

By Application

• Therapeutic Applications
• By Disease Type
• Neurological Disorders
• Rare Diseases
• Other Diseases
• Research Applications
• PCR
• Sequencing
• Other Research Applications
• Diagnostic Applications

By End User

• Hospitals
• Pharmaceutical & Biotechnology Companies
• Diagnostic Laboratories
• CROs and CMOs
• Academic Research Institutes

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • RoE
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East
  • GCC
    • Saudi Arabia
    • United Arab Emirates
    • Rest of GCC
  • Rest of the Middle East
• Africa

Recent Developments of Oligonucleotide Synthesis Industry:

• In November 2023, LCG Biosearch Technologies, a business unit of LGC Limited, acquired PolyDesign to enhance its oligonucleotide synthesis capabilities using PolyDesign's frit technology.
• In October 2023, Integrated DNA Technologies (IDT), a subsidiary of Danaher Corporation, opened its therapeutic oligonucleotide manufacturing facility in Coralville, Iowa. This facility will produce reagents for cGMP cell & gene therapy, including single-guide RNAs and HDR donor oligos.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst